DATATRAK by the Numbers - Analyst Blog

Loading...
Loading...

Ken Nagy, CFA


DATATRAK by the Numbers

DATATRAK International, Inc. (DATA) is a global technology and services company delivering electronic clinical (eClinical) solutions to support clinical research. Its software suite and service offerings are used to collect, review, report, store and submit to regulatory agencies clinical trial data electronically. While the competition uses an integrated heterogeneous solution (information silos), DATATRAK uses a unified system. The result is seamless communication, optimized data flow and lower costs.


Backdrop of Growth

•     Global pharmaceutical market is expected to grow 5-7% in 2011 to $880 billion
–    17 pharma emerging markets are forecasted to grow at 15-17% rate in 2011 to $170-180 billion
–    China is expected to grow 25-27% to more than $50 billion in 2011; it will now be the world's third-largest pharmaceutical market.
–    US will remain the single largest pharmaceutical market with 3-5% growth to reach $320-330 billion
•     Increase in Number of Clinical Trials Expected
–    Financing for biotechs to improve in 2011
–    Large pharma to continue biotech partnering in 2011
–    Pharma focus on emerging markets
–    Large pharma focusing R&D on new classes of medicines
•     Generics market is booming
–    76% of US prescriptions are generics
–    2011 $32 billion and 2012 $24 billion in patents will expire
•     Drug quality and safety
–    In 2010, 21 new drugs were approved in the US - the fewest since 2007 (19) which was a 24 year low
–    In 2009, drug recalls reached an unprecedented high of 1,748
–      FDA may strengthen rules for generics, medical devices, diabetes drugs, weight drugs

For a free copy of the full reserach report, please email scr@zacks.com with DATA as the subject.



DATATRAK INTL (DATA
): Free Stock Analysis Report


Zacks Investment Research
Loading...
Loading...
Posted In: Information TechnologySystems Software
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...